Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Drug Safety and Availability

Drug Safety and Availability

                        Drug Alerts and Statements
          Information about Nitrosamine Impurities in Medications
          Medication Guides
          Drug Safety Communications


                        Food and Drug Administration Overdose Prevention Framework
          Drug Shortages
          FDA Drug Safety Podcasts
          Information by Drug Class
          Medication Errors Related to CDER-Regulated Drug Products
          Postmarket Drug Safety Information for Patients and Providers
          Risk Evaluation and Mitigation Strategies | REMS
          Safe Use Initiative
          Drug Recalls
          Drug Supply Chain Integrity
          Multistate outbreak of fungal meningitis and other infections Home
          Drugs
          Drug Safety and Availability
          FDA Updates and Press Announcements on NDMA in MetforminDrug Safety and Availability FDA Updates and Press Announcements on NDMA in Metformin
  
  	
    Share
    Post
    Linkedin

    Email
    Print1/6/2021: UPDATE – Nostrum Laboratories voluntarily recalls an additional lot of extended release metformin
	**Update [01/6/2021]** FDA is alerting patients and health care professionals to Nostrum Laboratories’ voluntary recall of one additional lot of extended release (ER) metformin. The company is recalling the lot because the metformin may contain N-nitrosodimethylamine (NDMA) above the acceptable intake limit.

FDA publishes a recalled metformin list including details about metformin products that have been recalled. Patients taking recalled ER metformin should continue taking it until a doctor or pharmacist gives them a replacement or a different treatment option. It could be dangerous for patients with type 2 diabetes to stop taking their metformin without first talking to their health care professional. FDA recommends that health care professionals continue to prescribe metformin when clinically appropriate; FDA testing has not shown NDMA in immediate release (IR) metformin products (the most commonly prescribed type of metformin).

11/4/2020: UPDATE – Nostrum Laboratories voluntarily recalls extended release metformin
	**Update [11/4/2020]**FDA is alerting patients and health care professionals to Nostrum Laboratories’ voluntary recall of four lots of extended release (ER) metformin (two lots of 500 mg tablets and two lots of 750 mg tablets). The company is recalling metformin because it may contain N-nitrosodimethylamine (NDMA) above the acceptable intake limit.

FDA publishes a recalled metformin list including details about metformin products that have been recalled. Patients taking recalled ER metformin should continue taking it until a doctor or pharmacist gives them a replacement or a different treatment option. It could be dangerous for patients with type 2 diabetes to stop taking their metformin without first talking to their health care professional. FDA recommends that health care professionals continue to prescribe metformin when clinically appropriate; FDA testing has not shown NDMA in immediate release (IR) metformin products (the most commonly prescribed type of metformin).

10/5/2020: UPDATE – Marksans Pharma and Sun Pharmaceutical Industries voluntarily recall extended release (ER) metformin
	**Update [10/5/2020]** FDA is alerting patients and health care professionals to two voluntary recalls of extended release (ER) metformin by Marksans Pharma and Sun Pharmaceutical Industries. The companies are recalling metformin because it may contain N-nitrosodimethylamine (NDMA) above the acceptable intake limit.

Marksans expanded its voluntary recall to include 76 additional unexpired lots of metformin ER tablets (500 mg and 750mg) labeled as Time-Cap Labs.
	Sun voluntarily recalled one lot of Riomet ER, metformin hydrochloride for extended release oral suspension (500 mg per 5 mL).FDA publishes a recalled metformin list including details about metformin products that have been recalled.

Patients taking recalled ER metformin should continue taking it until a doctor or pharmacist gives them a replacement or a different treatment option. It could be dangerous for patients with type 2 diabetes to stop taking their metformin without first talking to their health care professional. FDA recommends that health care professionals continue to prescribe metformin when clinically appropriate.

The agency’s testing has not shown NDMA in immediate release (IR) metformin products (the most commonly prescribed type of metformin).

8/21/2020: UPDATE – Bayshore Pharmaceuticals voluntarily recalls extended release metformin
	**Update [8/21/2020]** FDA is alerting patients and health care professionals to Bayshore Pharmaceuticals’ voluntary recall of two lots of extended release (ER) metformin (one lot of 750 mg tablets and one lot of 500 mg tablets). The company is recalling metformin because it contains N-nitrosodimethylamine (NDMA) above the acceptable intake limit.

FDA publishes a recalled metformin list including details about metformin products that have been recalled. Patients taking recalled ER metformin should continue taking it until a doctor or pharmacist gives them a replacement or a different treatment option. It could be dangerous for patients with type 2 diabetes to stop taking their metformin without first talking to their health care professional. FDA recommends that health care professionals continue to prescribe metformin when clinically appropriate; FDA testing has not shown NDMA in immediate release (IR) metformin products (the most commonly prescribed type of metformin).

7/13/2020: UPDATE – Several companies voluntarily recall extended release metformin
	**Update [7/13/2020]** FDA is alerting patients and health care professionals to several voluntary recalls of extended release (ER) metformin by the companies listed below. The companies are recalling metformin due to the possibility the medicines could contain nitrosodimethylamine (NDMA) above the acceptable intake limit.

Granules Pharmaceuticals – 12 lots
	Lupin Pharmaceuticals – All lots (expansion of previous recall)
	Avkare (repackager for Amneal) – All lots
	PD-Rx Pharmaceuticals (repackager for Amneal) – 31 lots
	PD-Rx Pharmaceuticals (repackager for Marksans) – 26 lots
	The Harvard Drug Group (repackager for Apotex) – One lot (T-02134)
	Preferred Pharmaceuticals (repackager for Marksans) – Four lots (J0119M, K1419L, K2719J, A0220H)FDA published a recalled metformin list including details about metformin products that have been recalled. Patients taking recalled ER metformin should continue taking it until a doctor or pharmacist gives them a replacement or a different treatment option. It could be dangerous for patients with type 2 diabetes to stop taking their metformin without first talking to their health care professional. FDA recommends that health care professionals continue to prescribe metformin when clinically appropriate; FDA testing has not shown NDMA in immediate release (IR) metformin products (the most commonly prescribed type of metformin).

7/2/2020: UPDATE – The AAPS Journal publishes FDA paper on metformin testing
	**Update [7/2/2020]** Today, the AAPS Journal, an official journal of the American Association of Pharmaceutical Scientists, published FDA’s manuscript entitled, “A Cautionary Tale: Quantitative LC-HRMS Analytical Procedures for the Analysis of N-Nitrosodimethylamine in Metformin.”

This paper assesses the cause for the discrepancy between the NDMA values FDA found in its testing of metformin drug products and the values a private laboratory reported.

The private laboratory reported levels of NDMA above the acceptable intake limit in 16 of the 38 metformin products they tested. FDA immediately acted to analyze the same 38 samples. Overall, FDA observed that in orthogonal tests, the levels of NDMA, when present, were generally lower than reported by the private laboratory.

The paper provides additional details of FDA’s investigation and the importance of selection and validation of testing methods.

In summary, the agency found the private laboratory method to be inappropriate for quantifying NDMA in metformin drug products due to presumptive overestimation of NDMA caused by the presence of a substance that interfered with the testing results.

6/11/2020: UPDATE - FDA names companies recalling ER metformin
	**Update [6/11/2020]** FDA is alerting patients and health care professionals to five companies’ voluntary recalls of certain extended release (ER) metformin drugs. The agency recently announced it was in contact with five companies to recommend they voluntarily recall ER metformin because the agency’s testing showed N-Nitrosodimethylamine (NDMA) above the acceptable intake limit in certain lots.

Apotex – All lots
	Amneal – All lots
	Marksans (labeled as Time-Cap) – One lot (XP9004)
	Lupin – One lot (G901203)
	Teva (labeled as Actavis) – 14 lotsThere are additional companies that manufacturer ER metformin and supply a significant portion of the U.S. market, whose products are not being recalled at this time.

Patients taking recalled ER metformin should continue taking it until a doctor or pharmacist gives them a replacement or a different treatment option. It could be dangerous for patients with type 2 diabetes to stop taking their metformin without first talking to their health care professional. FDA recommends that health care professionals continue to prescribe metformin when clinically appropriate; FDA testing has not shown NDMA in immediate release (IR) metformin products (the most commonly prescribed type of metformin).

FDA updated its laboratory test results showing the levels of NDMA the agency has found in samples of metformin to date. FDA has also posted a second liquid chromatography-electrospray ionization-high resolution mass spectrometry (LC- ESI-HRMS) testing method to provide an option for regulators and industry to detect eight different nitrosamine impurities in metformin drug substances and drug products.

The agency is also asking all companies manufacturing ER metformin to evaluate the risk of their product containing NDMA above the acceptable intake limit and to test at-risk product before each batch is released onto the U.S. market. If testing shows NDMA above the acceptable intake limit, the companies must inform the agency and should not release the batch to the U.S. market.

5/28/2020: PRESS RELEASE – FDA Alerts Patients and Health Care Professionals to Nitrosamine Impurity Findings in Certain Metformin Extended Release Products
	Go to Press Release

2/3/2020: STATEMENT– FDA posts laboratory testing results for NDMA levels in metformin
	**[2/3/2020]** The U.S. Food and Drug Administration posted laboratory results showing N- Nitrosodimethylamine (NDMA) levels in some metformin products approved in the U.S. FDA has determined that the levels of NDMA in metformin products tested range from not detectable to low levels. To date, no sample of metformin that FDA has tested exceeds the acceptable daily intake for NDMA. FDA has not recommended metformin recalls in the U.S.

Metformin is a prescription drug used to control high blood sugar in patients with type 2 diabetes. Patients should continue taking metformin to keep their diabetes under control. It could be dangerous for patients with this serious condition to stop taking their metformin without first talking to their health care professionals.

FDA plans to post the methods used in laboratory testing of metformin in the near future. FDA is also collaborating with international regulators to share testing results for metformin, along with testing results for other drugs.

FDA will continue to monitor NDMA in metformin, along with other drugs products, and will provide timely updates of new developments, including product recalls. For more information about NDMA, visit FDA’s nitrosamines webpage.

FDA encourages health care professionals and patients to report adverse reactions or quality problems with any human drugs to the agency’s MedWatch Adverse Event Reporting program:

Complete and submit the report online at www.fda.gov/medwatch/report.htm; or
	Download and complete the form, then submit it via fax at 1-800-FDA-0178

2/3/2020: Laboratory testing results for NDMA in metformin
	Go to Laboratory Tests | Metformin

12/5/2019: STATEMENT - Statement from Janet Woodcock, M.D., director of FDA’s Center for Drug Evaluation and Research, on impurities found in diabetes drugs outside the U.S.
	Go to FDA Statement

FDA-published testing method to provide an option for regulators and industry to detect NDMA impurities

The links below are to FDA-published testing methods to provide an option for regulators and industry to detect nitrosamine impurities in metformin drug substances and drug products. These methods should be validated by the user if the resulting data are used to support a required quality assessment of the API or drug product, or if the results are used in a regulatory submission.

LC-HRMS method: an LC-MS method for the detection of NDMA in metformin drug substance and drug products.
	LC-ESI-HRMS method: an LC-HRMS method for the measurement of amounts of eight nitrosamine impurities in metformin drug substance and drug products

Resources for You

Search list of recalled metformin products
	Q & A: NDMA impurities in metformin products
	Nitrosamine Impurities in Medications
	Rigorous Detection of Nitrosamine Contaminants in Metformin Products: Balancing Product Safety and Product Accessibility

                                                                                  Content current as of:
      01/06/2021
              
              
Regulated Product(s)
		 DrugsTopic(s)
			  Safety - Issues, Errors, and ProblemsDrug Safety and Availability

          
                        Drug Alerts and Statements
          Information about Nitrosamine Impurities in Medications
          Medication Guides
          Drug Safety Communications


                        Food and Drug Administration Overdose Prevention Framework
          Drug Shortages
          FDA Drug Safety Podcasts
          Information by Drug Class
          Medication Errors Related to CDER-Regulated Drug Products
          Postmarket Drug Safety Information for Patients and Providers
          Risk Evaluation and Mitigation Strategies | REMS
          Safe Use Initiative
          Drug Recalls
          Drug Supply Chain Integrity
          Multistate outbreak of fungal meningitis and other infections
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop